Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnaire (AKQoL) (AKQOLVS)
The objective of this study is to translate the "AKQoL"-questionnaire which measures the quality of life of patients with actinic keratosis into German and to validate it for the Swiss population.
By using the technique of cognitive interviewing the investigators are focussing on the patients' understanding of the questions. The first session of cognitive interviews will show, where there is need for improvement in terms of misinterpreted phrases or vaguely worded questions. The goal is to rephrase the questions according to the feedback of the patients. The revised version will then be presented to a new population.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Actinic keratosis is a UV-induced skin disease, which presents as a reddish, squamous and sometimes itchy lesion. Actinic keratosis seems to have a negative impact on patients' quality of life. Esmann et al. elaborated on patients with actinic keratosis from Zealand, Denmark a questionnaire which measures the quality of life.
The objective of this study is to translate this questionnaire into German and to validate it for the Swiss population. This questionnaire might become part of a planned national register for data collection of patients with AK.
The investigators will assess the content validity of the questionnaire by using the technique of cognitive interviewing. The investigators are going to talk 34 patients with AK from the department of Dermatology, University Hospital Zurich through the translated version. Thereby, the investigators are focusing on the patients' understanding of the questions.
The first session of cognitive interviews will show, where there is need for improvement in terms of misinterpreted phrases or vaguely worded questions. The goal is to rephrase the questions in the sense that they become more clear and are understood by different interviewee in the same way. The revised version will then be presented to a new population. The performance of cognitive interview sessions and revisions will continue until the survey will be approved by at least 80% of the respondents.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8091
- University Hospital Zurich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with actinic keratosis of the department of Dermatology, University Hospital Zurich
- Male and Female subjects > 18 years of age
- Good understanding of written and spoken German
- Sufficient physical and mental capacity to comprehend the questions
- Written informed consent by the participant
Exclusion Criteria:
- Lack of informed consent
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: cognitive interviewing
individual cognitive interviewing, 30 minutes per patient
|
For the individual cognitive interviews we are using the two techniques "to think aloud" and the "verbal probing".
"To think aloud" means, that the patients are asked to express precisely what comes to their mind when reading the single questions.
This means, the interviewer is interested in the line of thoughts, which arise when reading the question.
Thereby, the problems which appear in the usually covert process of answering a question should be revealed.
In a second step, we are using the "verbal probing" technique to identify possible misunderstandings of the questions or difficulties with single phrases.
The interviewer asks further questions that target the patients' interpretation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intersubject agreement on validation of the questions of the AKQoL
Time Frame: 30 minutes per patient
|
Consistent answers by study participants on cognitive debriefing.
This is a qualitative, not a quantitative measure.
|
30 minutes per patient
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Günther Hofbauer, Prof.Dr.med., University of Zurich
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KEK-ZH-Nr. 2014-0252
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.